Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Chronic HCV genotype 1-infection prior to study enrollment. Chronic HCV-infection is defined as the following:~   * Positive for anti-HCV antibody (Ab) or HCV RNA \> 1,000 IU/mL at least 6 months before Screening, and positive for HCV RNA and anti-HCV Ab at the time of Screening; or~  * HCV RNA \> 1,000 IU/mL at the time of Screening with a liver biopsy consistent with chronic HCV-infection (or a liver biopsy performed prior to enrollment with evidence of chronic hepatitis C disease).~2. Screening laboratory result indicating HCV genotype 1b-infection.~3. Compensated cirrhosis defined as a Child-Pugh Score of 5 or 6 at Screening.~Exclusion Criteria:~1. Women who are pregnant or breastfeeding.~2. Positive test result for Hepatitis B surface antigen (HBsAg) or positive human immunodeficiency virus (HIV) antibody (confirmed by Western Blot).~3. Any current or past clinical evidence of Child-Pugh B or C classification or clinical history of liver decompensation such as ascites (noted on physical exam), variceal bleeding, or hepatic encephalopathy.~4. Confirmed presence of hepatocellular carcinoma indicated on imaging techniques such as computed tomography (CT) scan or magnetic resonance imaging (MRI) within 3 months prior to Screening or on an ultrasound performed at Screening (a positive ultrasound result will be confirmed with CT scan or MRI.)~5. Use of contraindicated medications within 2 weeks of dosing~6. Screening laboratory analyses showing any of the following abnormal laboratory results:~   * Calculated creatinine clearance (using Cockcroft-Gault method) \< 30 mL/min~  * Albumin \< 2.8 g/dL~  * International normalized ratio (INR) \> 1.8. Participants with a known inherited blood disorder and INR \> 1.8 may be enrolled with permission of the AbbVie Study Designated Physician.~  * Hemoglobin \< 10 g/dL~  * Platelets \< 25,000 cells per mm3~  * Total bilirubin \> 3.0 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir (Type: EXPERIMENTAL): Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).